Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Ulm – page 40

578 clinical trials in Ulm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ulm at a glance
578
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

578 trials in Ulm

Open in trial search

Hypercholesterolaemia

Not recruiting

Study Comparing Inclisiran and Bempedoic Acid for Lowering LDL Cholesterol in Patients with Atherosclerotic Cardiovascular Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Novartis Pharma GmbH

Dry age-related macular degeneration

Not recruiting

Study of Danicopan for Patients with Geographic Atrophy Due to Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Chronic lymphocytic leukaemia

Not recruiting

Study on Bendamustine, Obinutuzumab, Zanubrutinib, and Venetoclax for Patients with Relapsed Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

B-cell lymphoma+2

Not recruiting

Study on Lisocabtagene Maraleucel for Adults with Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lisocabtagene Maraleucel
  • Sponsor:Celgene Corp.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on Long-Term Safety and Tolerability of Iptacopan for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Hepatocellular carcinoma

Not recruiting

Study of Durvalumab, Tremelimumab, and Bevacizumab for Patients with Non-Resectable Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Growth hormone deficiency

Not recruiting

Study on the Effects of Somapacitan and Somatropin in Children with Growth Hormone Deficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of BIIB122 for Patients with Parkinson's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:N2-(3-(2-(2H-1,2,3-Triazol-2-Yl)Propan-2-Yl)-1-Cyclopropyl-1H-Pyrazol-5-Yl)-N4-Ethyl-5-(Trifluoromethyl)Pyrimidine-2,4-Diamine
  • Sponsor:Biogen Idec Research Limited

Hepatocellular carcinoma

Not recruiting

Study of Atezolizumab and Bevacizumab for Patients with High-Risk Hepatocellular Carcinoma After Surgery or Ablation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Clear cell papillary renal cell carcinoma

Not recruiting

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Chronic myeloid leukaemia

Not recruiting

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Ulm

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on colorectal cancer, acute myeloid leukemia, and various types of lymphomas. Studies are evaluating novel combination therapies and targeted treatments for patients with specific genetic mutations.

  • Metastatic Colorectal Cancer Treatment
  • B-Cell Lymphoma Therapies
  • Advanced Breast Cancer Studies

Multiple trials investigating innovative treatment approaches for blood cancers and solid tumors.

02 Neurological Disorders

Clinical research targeting multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. Studies are exploring new therapeutic agents and diagnostic tools.

  • Early-Stage Alzheimer's Treatment
  • Progressive MS Therapies
  • ALS Gene-Targeted Treatments

Innovative approaches in neurodegenerative disease management and treatment.

03 Autoimmune Conditions

Comprehensive studies on inflammatory bowel diseases, rheumatoid arthritis, and Sjögren's disease. Research focuses on novel biological therapies and long-term treatment options.

  • Crohn's Disease Treatments
  • Ulcerative Colitis Management
  • Autoimmune Disorder Therapies

Advanced therapeutic approaches for chronic inflammatory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.